Filing Flows

Filing Flows › 8-K events › Endovia Health Sciences

Endovia Health Sciences: entry into a material definitive agreement

Form 8-K filed Oct 27, 2026 · items 1.01

What the filing says

On October 22, 2026, Endovia Health Sciences, a Nevada corporation (the “Company”) entered into an Addendum to that certain Securities Purchase Agreement dated September 19, 2025 providing for an equity line of credit facility (the “ELOC Agreement”) with C/M Capital Master Fund, LP (the “Addendum”), pursuant to which p

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Endovia Health Sciences at a glance

Latest quarterQ1 2026
Revenue$4K
Revenue Y/Y-94%
Operating marginn/m
IndustryBeverages

Endovia Health Sciences, Q1 2026: revenue $4K (-94% year over year). The chart follows the revenue to costs, profit and cash.

Endovia Health Sciences: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent share offerings

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.